BioNTech (NASDAQ:BNTX) Shares Down 2.4%

Shares of BioNTech SE (NASDAQ:BNTX) traded down 2.4% on Friday . The stock traded as low as $95.61 and last traded at $96.64. 205,372 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 666,949 shares. The stock had previously closed at $99.00.

Analyst Ratings Changes

Several analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $113.00 price objective on shares of BioNTech in a research report on Friday. Canaccord Genuity Group restated a “buy” rating and set a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. Evercore ISI assumed coverage on BioNTech in a report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price for the company. TD Cowen increased their target price on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Finally, UBS Group cut their target price on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $111.70.

BioNTech Stock Performance

The business has a fifty day simple moving average of $90.83 and a two-hundred day simple moving average of $95.91. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. The company has a market cap of $22.78 billion, a P/E ratio of 198.00 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. On average, sell-side analysts anticipate that BioNTech SE will post -1.99 EPS for the current year.

Institutional Trading of BioNTech

Institutional investors have recently made changes to their positions in the business. Baillie Gifford & Co. grew its holdings in BioNTech by 1.0% during the 4th quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock valued at $917,056,000 after buying an additional 86,343 shares in the last quarter. Primecap Management Co. CA grew its holdings in BioNTech by 2.8% during the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after buying an additional 131,490 shares in the last quarter. Harding Loevner LP purchased a new position in BioNTech during the 4th quarter valued at approximately $410,984,000. Flossbach Von Storch AG grew its holdings in BioNTech by 1.0% during the 4th quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock valued at $374,526,000 after buying an additional 35,445 shares in the last quarter. Finally, Capital World Investors grew its holdings in BioNTech by 0.5% during the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock valued at $87,002,000 after buying an additional 4,369 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.